Hope on the Horizon: Top MDS & CMML Breakthroughs from ASH 2025

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Sangeetha Venugopal, M.D., is a board-certified hematologist who trained at renowned institutions, including Montefiore Medical Center and the Icahn School of Medicine at Mount Sinai in New York, and completed an additional leukemia-focused fellowship at the UT MD Anderson Cancer Center in Houston, Texas. A well-published clinician-investigator, Dr. Venugopal focuses research on improving treatment outcomes for patients with myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN), through clinical trials, translational investigations, and precision medicine approaches. Dr. Venugopal has a particular interest in identifying novel targeted therapies, elucidating mechanisms of treatment resistance, and developing strategies to eradicate measurable residual disease in AML.